| Literature DB >> 26147888 |
Jian Yin1, Juan Wen1, Dong Hang1, Jing Han1, Jie Jiang1, Ci Song1, Yao Liu2, Jibin Liu3, Li Liu4, Liguo Zhu5, Jianguo Chen6, Xiangjun Zhai5, Shuanghua Xie7, Zhibin Hu1, Hongbing Shen1, Min Dai7, Ni Li7.
Abstract
Caspase recruitment domain family, member 8 (CARD8) can coordinate innate and adaptive immune responses and sensitize cells to apoptosis, which may participate in tumorigenesis of virus-induced hepatocellular carcinoma (HCC) and cervical cancer. By bioinformatics analyses, we identified several single nucleotide polymorphisms (SNPs) within a new identified long non-coding RNA (lncRNA) as expression quantitative trait loci (eQTLs) for CARD8. In this study, we therefore hypothesized that CARD8 eQTLs SNPs within lncRNA may influence the risk of HCC and cervical cancer. We performed two independent case-control studies of 1,300 cases with HBV-positive HCC and 1,344 normal controls, together with 1,486 cervical cancer patients and 1,536 control subjects to test the association between eQTLs SNP (rs7248320) for CARD8 and the risk of HCC and cervical cancer. The variant genotype of rs7248320 was significantly associated with increased risk of HCC and cervical cancer [GG vs. AA/GA: adjusted odds ratio (OR) = 1.28, 95% confidence interval (CI) = 1.03-1.61, P = 0.028 for HCC; adjusted OR = 1.34, 95% CI = 1.09-1.66, P = 0.006 for cervical cancer]. Moreover, the effect of rs7248320 on cervical cancer risk was more prominent in premenopausal women. Further interactive analysis detected a significantly multiplicative interaction between rs7248320 and menopausal status on cervical cancer risk (P = 0.018). These findings suggest that CARD8 eQTLs SNP may serve as a susceptibility marker for virus-related HCC and cervical cancer.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26147888 PMCID: PMC4492972 DOI: 10.1371/journal.pone.0132352
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Information of primers for Sequenom MassARRAY Iplex.
| SNP | Primer | Sequence (5’-3’) |
|---|---|---|
|
| 1st-PCR Primer | ACGTTGGATGACAGCCTGGAGGAATCTAAG |
| 2nd-PCR Primer | ACGTTGGATGTTCTCTTAACGTCCTCTTTC | |
| Extend Primer | TCTTCTCCAAGATCGAAT |
Demographic and selected variables in HCC cases and controls.
| Variables | HCC | Controls |
|
|---|---|---|---|
| ( | ( | ||
|
| 52.9±10.5 | 52.7±11.1 | 0.765 |
|
| 0.613 | ||
|
| 693(53.3) | 703(52.3) | |
|
| 607(46.7) | 641(47.7) | |
|
| 0.914 | ||
|
| 1104(84.9) | 1139(84.7) | |
|
| 196(15.1) | 205(15.3) | |
|
| 0.287 | ||
|
| 774(59.5) | 772(57.4) | |
|
| 526(40.5) | 572(42.6) | |
|
| <0.001 | ||
|
| 764(58.8) | 602(44.8) | |
|
| 536(41.2) | 742(55.2) |
Abbreviation: SD, standard deviation.
Demographic and selected variables between cervical cancer cases and controls.
| Variables | Cases | Controls |
|
|---|---|---|---|
| ( | ( | ||
|
| 53.85±12.70 | 53.21±11.91 | 0.159 |
|
| <0.001 | ||
|
| 62(4.2) | 22(1.4) | |
|
| 1404(95.8) | 1514(98.6) | |
|
| 0.002 | ||
|
| 608(41.5) | 598(38.9) | |
|
| 769(52.5) | 878(57.2) | |
|
| 81(5.5) | 60(3.9) | |
|
| 0.335 | ||
|
| 278(19.0) | 313(20.4) | |
|
| 1187(81.0) | 1223(79.6) | |
|
| 0.001 | ||
|
| 620(42.3) | 731(48.3) | |
|
| 406(27.7) | 405(26.8) | |
|
| 440(30.0) | 377(24.9) |
Abbreviation: SD, standard deviation.
Logistic regression analyses on associations between single nucleotide polymorphism rs7248320 (A>G) genotypes and risk of hepatocellular carcinoma and cervical cancer.
| Genotype | Hepatocellular carcinoma | Cervical cancer | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients (N = 1300) | Controls (N = 1344) | OR(95%CI) |
| OR(95%CI) |
| Patients (N = 1486) | Controls (N = 1536) | OR(95%CI) |
| OR(95%CI) |
| |
|
| ||||||||||||
|
| 524(41.3%) | 564(42.4%) | 1 | 1 | 535(39.5%) | 614(42.3%) | 1 | 1 | ||||
|
| 540(42.5%) | 600(45.1%) | 0.97(0.82–1.14) | 0.708 | 0.97(0.82–1.15) | 0.755 | 587(43.4%) | 640(44.1%) | 1.03(0.88–1.20) | 0.706 | 1.05(0.89–1.24) | 0.519 |
|
| 206(16.2%) | 167(12.5%) | 1.33(1.05–1.68) |
| 1.27(1.00–1.61) | 0.053 | 231(17.1%) | 196(13.5%) | 1.37(1.10–1.70) |
| 1.38(1.10–1.73) |
|
|
| 1.35(1.08–1.68) |
| 1.28(1.03–1.61) |
| 1.35(1.10–1.65) |
| 1.34(1.09–1.66) |
| ||||
CI, confidence interval; OR, odds ratio. The boldface values represent these P values were less than 0.05.
aAdjusted for age, gender, smoking status and drinking status.
bAdjusted for age, smoking status, menopausal status, family history of any cancer and parity.
Stratified analyses on association between rs7248320 genotypes and HCC risk.
| Variables | Patients/Controls N (%) | OR(95%CI) |
| |
|---|---|---|---|---|
| AA/GA | GG | |||
|
| 0.280 | |||
|
| 560(82.7)/607(87.6) | 117(17.3)/86(12.4) | 1.41(1.04–1.92) | |
|
| 504(85.0)/557(87.3) | 89(15.0)/81(12.7) | 1.10(0.79–1.53) | |
|
| 0.133 | |||
|
| 900(83.0)/985(87.3) | 184(17.0)/143(12.7) | 1.36(1.07–1.73) | |
|
| 164(88.2)/179(88.2) | 22(11.8)/24(11.8) | 0.77(0.38–1.55) | |
|
| 0.625 | |||
|
| 617(81.4)/657(86.2) | 141(18.6)/105(13.8) | 1.35(1.01–1.80) | |
|
| 447(87.3)/507(89.1) | 65(12.7)/62(10.9) | 1.20(0.83–1.75) | |
|
| 0.922 | |||
|
| 607(81.4)/505(84.9) | 139(18.6)/90(15.1) | 1.29(0.96–1.73) | |
|
| 457(87.2)/659(89.5) | 67(12.8)/77(10.5) | 1.32(0.92–1.88) | |
aAdjusted for age, gender, smoking status and drinking status (excluded the stratified factor in each stratum).
b P-value for the heterogeneity test.
Stratified analyses on association between rs7248320 genotypes and cervical cancer risk.
| Variables | Patients/ Controls N (%) | OR(95%CI) |
| |
|---|---|---|---|---|
| AA/GA | GG | |||
|
| 0.118 | |||
|
| 554(79.5)/679(85.3) | 143(20.5)/117(14.7) | 1.59(1.21–2.10) | |
|
| 567(86.6)/575(87.9) | 88(13.4)/79(12.1) | 1.13(0.81–1.56) | |
|
| 0.498 | |||
|
| 45(86.5)/20(90.9) | 7(13.5)/2(9.1) | 2.49(0.42–14.79) | |
|
| 1076(82.8)/1234(86.4) | 224(17.2)/194(13.6) | 1.34(1.09–1.66) | |
|
| 0.014 | |||
|
| 470(78.9)/508(86.5) | 126(21.1)/79(13.5) | 1.82(1.33–2.48) | |
|
| 651(86.1)/746(86.4) | 105(13.9)/117(13.6) | 1.07(0.80–1.42) | |
|
| 0.830 | |||
|
| 210(82.7)/256(86.2) | 44(17.3)/41(13.8) | 1.41(0.87–2.28) | |
|
| 911(83.0)/998(86.6) | 187(17.0)/155(13.4) | 1.33(1.06–1.68) | |
|
| 0.305 | |||
|
| 455(80.2)/612(86.3) | 112(19.8)/97(13.7) | 1.6(1.19–2.16) | |
|
| 319(83.5)/336(85.1) | 63(16.5)/59(14.9) | 1.09(0.73–1.62) | |
|
| 347(86.1)/306(88.4) | 56(13.9)/40(11.6) | 1.29(0.83–2.00) | |
aAdjusted for age, smoking status, menopausal status, family history of any cancer and parity (excluded the stratified factor in each stratum).
b P-value for the heterogeneity test.
Crossover analysis in genotypes-menopausal status interaction study on cervical cancer.
| Genotype | Menopausal status | Patients (N = 1486) | Controls (N = 1536) | OR(95%CI) |
|
|---|---|---|---|---|---|
|
| Menopause | 642(48.15) | 759(51.53) | 1 | |
|
| Premenopausal | 471(34.79) | 517(35.10) | 1.80(1.42–2.29) | <0.001 |
|
| Menopause | 105(7.75) | 117(7.94) | 1.06(0.79–1.41) | 0.700 |
|
| Premenopausal | 126(9.31) | 80(5.43) | 3.18(2.24–4.52) | <0.001 |
|
|
|
aAdjusted for age, smoking status, family history of any cancer and parity.
b P value for multiplicative interaction.